Product Information
LORAZEPAM 2 MG/ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $2.1715 per ML under NDC 00641604825. Its NADAC has been published 94 times since Dec 18, 2024.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AP.
Strength
2 mg/mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00641604825
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
LORAZEPAMApproval Type
New Drug (NDA)
FDA Application
NDA018140FDA Approved
Before 1982
TE Code
AP
On Market Since
7/25/1980
Pharmacological Classes
Price Statistics
The NADAC for LORAZEPAM 2 MG/ML VIAL has been published 94 times since Dec 18, 2024, and over the history we have for it it has risen 99.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1715 per ML |
|---|---|
| All-time high | $2.1715 (Sep 30, 2026) |
| All-time low | $1.0891 (Dec 18, 2024) |
| 52-week high | $2.1715 |
| 52-week low | $1.0891 |
| Median price | $1.0891 |
| Average price | $1.3440 |
| Largest weekly change | +54.6% (Mar 18, 2026) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 69% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lorazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LORAZEPAM 2 MG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for LORAZEPAM 2 MG/ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $2.1715 per ML (NDC 00641604825), effective Sep 30, 2026.
How has the price of LORAZEPAM 2 MG/ML VIAL changed over time?
Over the history we have for it, the NADAC for LORAZEPAM 2 MG/ML VIAL has risen 99.4%. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for LORAZEPAM 2 MG/ML VIAL?
Since Dec 18, 2024, the NADAC for LORAZEPAM 2 MG/ML VIAL has ranged from a low of $1.0891 (Dec 18, 2024) to a high of $2.1715 (Sep 30, 2026), with a median of $1.0891 per ML.
Are there cheaper alternatives to LORAZEPAM 2 MG/ML VIAL?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LORAZEPAM 20 MG/10 ML VIAL, is $0.6796 per ML — about 69% below LORAZEPAM 2 MG/ML VIAL.
Who manufactures LORAZEPAM 2 MG/ML VIAL?
LORAZEPAM 2 MG/ML VIAL (NDC 00641604825) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.